Yeah I always enjoy his posts. I do wonder if the company is able to recruit more heavily towards the mild population this second half of the recruiting cycle. At the same time the SPA was approved with the 2 subgroups so it may not matter. It's just odd that the results have gotten less impressive over time. It seems it would be more equal as far as the severity of patients over the course of the study. Certainly makes it more of a gamble to me.
you make a good point about the SPAs. If I were Remi I would only recruit patients in the mild category from here on out,...just forget about moderates. or vastly under recruit them by a 3-1 ratio.. (who will still received the product off label eventually)...go for broke. "Be bold in all things." what is the value of information if you cannot use it?
Market Data 
Markets 
AI
